Clinical trials sponsored by Baxter Healthcare in conjunction with the NIH using bi-weekly infusions of Gammaglobulin has completed a third phase trial. Caregivers and clinical professionals have seen a DRAMATIC change in Alzheimer's patients who are believed to have received the infusions of Gammaglobulin. Improvements were observed in quality of life, daily functioning and activities, appetite, grooming and other life activities that are often disrupted and often halted by the progression of Alzheimer's. At the completion of each participants' trial, the infusions were halted by Baxter and were not offered to the participants as an option to continue use, even though personal observations indicated definite improvements. Months after the completion of the trial and after infusions were stopped, the original Alzheimer's symptoms may have OR have returned in at least one or some of the participants in the study. Baxter must take responsibility and allow these persons the choice to continue these infusions if they choose for the lifetime of the patient at no charge. Baxter, the NIH and the FDA are wasting time with this deadly, cruel disease which has now inflicted more then 5.3 million Americans alone. Tell Baxter, the NIH and the FDA to get IVIG (infusions of Gammaglobulin) approved and on the market at an affordable price for all persons with Alzheimer's disease to have and use for the treatment of and the slowing of the progression of Alzheimer's disease.